Bukwang announces patent registration of SOL-804 in 32 countries
registration in more 6 countries, including Korea in this year Bukwang Pharmaceutical Co., Ltd. (Bukwang) announced that the composition...
top of page
R&D NEWS
Bukwang Announces the result of SOL-804’s Phase 1 clinical trial
Result : It has similar pharmacokinetic properties with low-doses compared to the control group with high-doses. Bukwang will decide the...
Bukwang Announces Completion of SOL-804’s Phase 1 clinical trial
- The result will be shown in March : to confirm the equivalent effectiveness with low doses compared to the control medicine - This...
Bukwang expanded the partnership of ‘Aprovel and CoAprovel’ to General Hospitals
-Bukwang made a contract with Sanofi-Aventis Korea on sales-marketing expansion Bukwang Pharmaceutical(CEO Yoo Hee Won) announced that...
Bukwang initiates dosing of SOL-804 in the phase 1 study
- an improved treatment of prostate cancer ,the study will be ended within the first half of 2022 Bukwang Pharmaceutical Co., Ltd....
Bukwang received approval of a new drug ‘Ozanex cream’ , a topical antibiotic
-A short-term topical impetigo treatment from Ferrer Healthcare, Spain -It is a new drug approved from FDA and EMA and also will be...
Bukwang registered a composition patent for SOL-804 in the U.S.
approved in the U.S.,Europe, Japan, Eurasia, Australia, and Mexico Bukwang Pharmaceutical (“Bukwang”) announced that its subsidiary, Dyna...
Approval of phase 1 clinical study for anticancer drug, SOL-804
The modified drug for metastatic castration-resistant prostate cancer, expectation of the fast result Bukwang Pharmaceutical announced...
Contera Pharma, a subsidiary of Bukwang, has partnership with Abzu
to design RNA therapeutics for rare diseases using x AI technology Contera Pharma, a subsidiary of Bukwang, is focused on developing new...
Bukwang concluded the patient recruitment for the clinical trial of covid-19 treatment
Bukwang Pharmaceutical Co., Ltd. announced that they concluded patient recruitment for the phase 2 clinical trial of covid-19 treatment...
Bukwang confirmed Levovir showed tendency of reducing virus from Phase 2 clinical trial topline data
Bukwang Pharmaceutical Co., Ltd. announced the topline result of CLV-201, the Phase 2 clinical trial of Levovir as COVID-19 treatment....
Bukwang initiates dosing of JM-010 in the US phase 2 study
Bukwang Pharmaceutical Co., Ltd. (Bukwang) announced that JM-010 has been administered to the first patient in phase 2 study in Europe....
Bukwang Pharmaceutical increased the number of patients for the clinical trial of covid-19 treatment
Bukwang increased the number of patients from 40 to 80 Bukwang announced that they decided to increase the patients of the second...
Bukwang received US FDA approval for phase 2 clinical study IND of Levovir, as a COVID-19 treatment.
Bukwang Pharmaceutical Co., Ltd. (“Bukwang”) announced that they received US FDA approval for Levovir(active ingredient: Clevudine) , as...
Bukwang concluded the 60 patients recruitment for the clinical trial of covid-19 treatment
Bukwang Pharmaceutical Co., Ltd. announced that they concluded 60 patients recruitment for the clinical trial of covid-19 treatment with...
Bukwang registered composition patent for SOL-804 in Europe
- approved in Europe and Eurasia, Australia, Mexico - Phase 1 study will be conducted in Europe after Korea Bukwang Pharmaceutical...
Contera Pharma, subsidiary of Bukwang, elected specialists in global CNS area
- CEO : Thomas N. Sager , the former development expert of lundbeck - Head of BD : Anders Brandt Elvang, the former BD executive of...
ImmPACT Bio USA Inc. Raises $18 Million In Series A Financing
Company is creating innovative cellular therapeutics for solid tumors CAMARILLO, Calif., Aug. 18, 2020 /PRNewswire/ -- ImmPACT Bio USA...
Bukwang has been granted a patent for its antiviral agent, Levovir, as COVID-19 treatment.
- Efficacy against SARS-Cov-2 - Application under Patent Cooperation Treaty (PCT) has also been filed Bukwang Pharmaceutical Co., Ltd....
Dyna Therapeutics, subsidiary of Bukwang, registered patent of anticancer drug SOL-804 in Japan
Patent examination ongoing in Korea, USA, Europe, China, India etc. Bukwang Pharmaceutical (“Bukwang”) announced that its subsidiary,...
Contera Pharma, subsidiary of Bukwang, raised 51 billion KRW in Series B financing round
Contera Pharma (“Contera”), subsidiary of Bukwang Pharmaceutical (“Bukwang”), announced 51 billion KRW Series B financing from Korean...
Bukwang exports hipnotic-sedative emergency drug for COVID-19 related treatment
Midazolam export to Luxembourg and France completed, the United Kingdom and Chile under discussion Bukwang announced that it has exported...
Bukwang’s antiviral drug, Levovir®, confirms antiviral effect against coronavirus
Levovir demonstrated comparable efficacy to KALETRA® against coronavirus in vitro Bukwang Pharmaceutical Co., Ltd. announced that in...
Bukwang Initiates Exportation of its In-House-Developed Drug, DEXIDⓇ to Southeast Asia
- Kalbe International to take on sales in 2 approved countries Bukwang Pharmaceutical Co., Ltd (Bukwang) announced that its in-house...
ProteKt Therapeutics Raises $3.6 Million in Post-incubation Financing
ProteKt Therapeutics, a biotech company developing new PKR kinase inhibitor based therapies for neurodegenerative diseases including ...
ASLAN PHARMACEUTICALS AND BUKWANG PHARMACEUTICAL ESTABLISH A JOINT VENTURE, JAGUAHR THERAPEUTICS, TO
ASLAN spins out pre-clinical assets in joint venture with Bukwang to form JAGUAHR Therapeutics with Bukwang investing up to $5million to...
Contera Pharma, a subsidiary of Bukwang Pharmaceutical, attracts investment from Medici Investment
3 million dollars invested by Medici Investment European Clinical phase 2 study of JM-010 to treat dyskinesia in Parkinson’s disease has...
University of Dundee partners with Bukwang Pharmaceutical Company to tackle new drug treatment for P
The University of Dundee‘s Drug Discovery Unit (DDU) has announced a multi-million-pound partnership with Korean-based Bukwang...
BNO BIO, a joint company by Bukwang and OCI, invests in a bio-venture that develop a technology in e
BNO BIO has invested $1 million in Nucleix, an Israeli bio-venture The first global investment by BNO BIO since its inception Going...
Bukwang Announced commencement of Phase 2 Clinical Study of JM-010 in major European countries
- to be completed within 2 years Bukwang Pharmaceutical (“Bukwang”) announced today that the phase 2 clinical study of JM-010, a new...
Bukwang Announces Completion of MLR-1023’s Phase 2b clinical trial
- Fast speed of study progression, expecting results in January next year MLR-1023’s phase 2b study is completed on December 14th EST....
Bukwang Announces completion of dosing of MLR-1023’s phase 2b study.
Bukwang announced that it has completed the clinical trials of MLR-1023, a new diabetic drug candidate. This is a phase 2b clinical trial...
Bukwang Announces approval of Clinical Trial Application by European authority to initiate Phase 2 s
Bukwang Pharmaceutical announces that the company’s application to conduct phase 2 clinical study for new CNS drug candidate 'JM-010' has...
Bukwang Pharmaceutical Co., Ltd. entered into a license transfer agreement of Rivoceranib for 40 bil
On August 14, 2018, the two companies signed a contract to transfer all rights of Rivoceranib held by Bukwang Pharmaceutical to HLB...
Bukwang Pharmaceutical Co., Ltd. completed global phase 2b study of MLR-1023, novel candidate for ty
- 400 patient enrollment in 61 sites (US & KR) Bukwang Pharmaceutical Co., Ltd. announced completion of global Phase 2b study of...
Bukwang Pharmaceutical Co., Ltd. expects to complete patients enrollment for global phase 2b study o
More than 360 patients dosed out of 400 patients in the US and Korea MLR-1023, a new anti-diabetic drug from Bukwang Pharmaceutical, is...
Bukwang-OCI, Pharmaceutical and Bio industry Business alliance
- Both companies agree 50:50 joint venture on May 30th - Starting in July, a joint venture invests 10 billion KRW annually to new drug...
Bukwang Pharmaceuticals, began to expand the lineup of anticancer drugs - Development of drugs for
Bukwang has recently established a small but solid position in the anticancer drug industry, which is considered as the exclusive product...
Bukwang Pharm, income from AurKa Pharma investment - Upfront approx. 6 billion won, additional miles
Bukwang Pharmaceutical announced that it owns a 5.4 percent stake in AurKa Pharma, Inc., which company signed contract with Eli Lilly on...
Bukwang initiates phase 3 study with lurasidone HCl for patients with Schizophrenia
Bukwang Pharmaceutical Co., Ltd. (“Bukwang”) announced on April 9, 2018 that it has randomized the first subject into the treatment arm...
Listening to shareholders’ opinions and answering to inquiries, Bukwang gained shareholders’ approva
Bukwang Pharmaceutical Co., Ltd. (“Bukwang”) announced that all of the seven resolutions proposed to its 58th general meeting were...
Bukwang pushes on its export of DEXID, a self-developed incrementally modified drug, to Southeast As
Bukwang launches DEXID, a self-developed IMD, in four Southeast Asian countries, including Philippines, Vietnam, etc. In 2016, Bukwang...
Bukwang Pharmaceutical Co., Ltd.(“Bukwang”) registered patents on a therapeutic candidate for Levodo
Bukwang said it registered patents on the use and composition of ‘JM-010’ with Korean Intellectual Property Office (Title : Combinations...
Bukwang Pharmaceutical Co., Ltd. a novel candidate for type 2 diabetes, MLR-1023 is undergoing globa
Bukwang Pharmaceutical Co., Ltd. announced on today that global phase 2b study of MLR-1023 in both US and Korea have completed the...
Acer Therapeutics, in which Bukwang is investing, is to go public - through merger with Opexa Therap
Acer Therapeutics Inc. (“Acer”), an ultra orphan drug development company in which Bukwang has been investing since 2015, announced that...
Bukwang announces the conclusion of an exclusive license agreement with Sumitomo Dainippon Pharma on
Bukwang Pharmaceutical Co., Ltd. (“Bukwang”) announced today that the company has concluded an exclusive license agreement with Sumitomo...
Bukwang Pharmaceutical Co., Ltd. received 5.8 B KRW from its investment in CoLucid, an American pha
On March 28th 2017, Bukwang Pharmaceutical Co., Ltd.(“Bukwang”) announced that it received the distribution of approximately 5,200,000...
Bukwang Pharmaceutical Co., Ltd. LID treatment ‘JM-010’ is approved for Orphan Drug Designation
Bukwang recently announced that Ministry of Food and Drug Safety (MFDS) has granted JM-010 for the treatment of levodopa-induced...
Bukwang launched cosmetic products to target Dermocosmetic industry Importing ‘Repavar’ products fro
Bukwang Pharmaceutical Co., Ltd., is now ready to enter into new industry by importing and developing cosmetic products. Bukwang is...
Bukwang Pharmaceutical Co., Ltd, submitted Phase 2b IND for new diabetic drug candidate, MLR-1023
Bukwang Pharmaceuticals Co., Ltd. (Bukwang) announced that it has submitted to MFDS an IND for conducting Phase 2b clinical trial for...
| Korean |
bottom of page